Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition

Hossan MS 1 , Chan ZY 2 , Collins HM 3 , Shipton FN 2 , Butler MS 4 , Rahmatullah M 5 Show all authors , Lee JB 6 , Gershkovich P 3 , Kagan L 6 , Khoo TJ 2 , Wiart C 2 , Bradshaw TD 7

Affiliations 

  • 1 School of Pharmacy, Centre for Biomolecular Sciences, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK; School of Pharmacy, University of Nottingham Malaysia Campus, Jalan Broga, Semenyih, 43500, Selangor, Malaysia. Electronic address: bdshahadat@yahoo.com
  • 2 School of Pharmacy, University of Nottingham Malaysia Campus, Jalan Broga, Semenyih, 43500, Selangor, Malaysia
  • 3 School of Pharmacy, Centre for Biomolecular Sciences, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK
  • 4 Institute for Molecular Bioscience, University of Queensland, St. Lucia, QLD, 4072, Brisbane, Queensland, Australia
  • 5 Department of Pharmacy, University of Development Alternative, Lalmatia, Dhaka, 1207, Bangladesh
  • 6 Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA
  • 7 School of Pharmacy, Centre for Biomolecular Sciences, The University of Nottingham, University Park, Nottingham, NG7 2RD, UK. Electronic address: tracey.bradshaw@nottingham.ac.uk
Cancer Lett, 2019 07 01;453:57-73.
PMID: 30930233 DOI: 10.1016/j.canlet.2019.03.034

Abstract

Natural products possess a significant role in anticancer therapy and many currently-used anticancer drugs are of natural origin. Cerberin (CR), a cardenolide isolated from the fruit kernel of Cerbera odollam, was found to potently inhibit cancer cell growth (GI50 values 60% bioavailability and rapid absorption; doses of 1-10 mg/kg CR were predicted to maintain efficacious unbound plasma concentrations (>GI50 value). CR's potent and selective anti-tumour activity, and its targeting of key signalling mechanisms pertinent to tumourigenesis support further preclinical evaluation of this cardiac glycoside.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications